Opioid plasma concentration during switching from morphine to methadone: preliminary data

[1]  F. Fulfaro,et al.  Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Pasternak,et al.  Strategies to manage the adverse effects of oral morphine: an evidence-based report. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Kaasa,et al.  Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine , 2000, European Journal of Clinical Pharmacology.

[4]  S. Mercadante.  Opioid rotation for cancer pain , 1999, Cancer.

[5]  S. Mercadante,et al.  Rapid switching from morphine to methadone in cancer patients with poor response to morphine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Zecca,et al.  Diclofenac does not modify methadone bioavailability in cancer patients. , 1999, Journal of pain and symptom management.

[7]  S. Mercadante.  The role of morphine glucuronides in cancer pain , 1999, Palliative medicine.

[8]  S. Mercadante,et al.  Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Brunelli,et al.  Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Bruera,et al.  Dose ratio between morphine and methadone in patients with cancer pain , 1998, Cancer.

[11]  R. Moore,et al.  Systematic review of factors affecting the ratios of morphine and its major metabolites , 1998, Pain.

[12]  S. Mercadante.  Methadone in cancer pain , 1997, European journal of pain.

[13]  E. Zecca,et al.  An update on the clinical use of methadone for cancer pain , 1997, Pain.

[14]  A. Vigano,et al.  Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators , 1996, PAIN.

[15]  E. Bruera,et al.  Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine , 1996, Cancer.

[16]  K. Foley,et al.  Opioid pharmacotherapy in the management of cancer pain. A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration , 1995, Cancer.

[17]  E. Bruera,et al.  Respiratory depression in a patient receiving oral methadone for cancer pain. , 1995, Journal of pain and symptom management.

[18]  M. Hammarlund-Udenaes,et al.  Pharmacokinetics and pharmacodynamics of morphine‐3‐glucuronide in rats and its influence on the antinociceptive effect of morphine , 1993, Biopharmaceutics & drug disposition.

[19]  C. Poynton,et al.  Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia , 1992, The Lancet.

[20]  T. Hedner,et al.  Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat , 1992, Pain.

[21]  R. Portenoy,et al.  Chronic nausea and morphine-6-glucuronide. , 1991, Journal of pain and symptom management.

[22]  E. Zecca,et al.  Plasma morphine and morphine-6-glucuronide patterns in cancer patients after oral, subcutaneous, sublabial and rectal short-term administration. , 1991, International journal of clinical pharmacology research.

[23]  Maree T. Smith,et al.  Morphine-3-Glucuronide — A potent antagonist of morphine analgesia , 1990, Pain.

[24]  M. Ivarsson,et al.  Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum: a possible explanation for previous observations on incomplete opioid cross-tolerance. , 1989, Pharmacology & toxicology.

[25]  J. Sear,et al.  Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. , 1989, British journal of anaesthesia.